Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vext ScienceFRA:VV5 59 Debt-to-EBITDA is 2.03 as of Mar. 2026, which is 27% above its 10-year median of 1.60. GuruFocus rates FRA:VV5 with a GF Score™ of 59/100 and a GF Value™ of €1.01. The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Vext Science ranks worse than 76.65% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vext Science's Debt-to-EBITDA or its related term are showing as below:
FRA:VV5'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -19.56 Med: 1.6 Max: 6.82
Current: 4.08
During the past 9 years, the highest Debt-to-EBITDA Ratio of Vext Science was 6.82. The lowest was -19.56. And the median was 1.60.
FRA:VV5's Debt-to-EBITDA is ranked worse than 76.65% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs FRA:VV5: 4.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vext Science Debt-to-EBITDA Related Terms
Vext Science Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vext Science's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vext Science's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Vext Science (FRA:VV5) has a Debt-to-EBITDA of 2.03 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vext Science. This is 27% above median its historical median of 1.60. According to the industry distribution chart, Vext Science ranks #522 out of 681 companies in the Drug Manufacturers industry, placing it in the top 76.7%.
Is Vext Science's Debt-to-EBITDA too high?
Vext Science's current Debt-to-EBITDA of 2.03 is 27% above median its 10-year median of 1.60. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Vext Science's value of 2.03 is 23.8% above this industry median. Based on the distribution chart, Vext Science ranks #522 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #522 out of 681 companies for Debt-to-EBITDA. This places Vext Science in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Vext Science's value of 2.03 is 23.8% above this benchmark. While the company's 10-year median is 1.60 vs. the industry median of 1.64, Vext Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current Debt-to-EBITDA of 2.03 is 23.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vext Science. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current Debt-to-EBITDA is 2.03, which is 27% above median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current Debt-to-EBITDA of 2.03. The stock's GF Value™ is €1.01, compared to a current price of €0.17 — trading 83.7% below its estimated fair value. The current Debt-to-EBITDA is 2.03, which is 27% above median its 10-year median of 1.60 and 23.8% above the Drug Manufacturers industry median of 1.64. Vext Science's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Debt-to-EBITDA is 2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.17 is trading 83.7% below its estimated GF Value™ of €1.01.
Key valuation signals for FRA:VV5:
Debt-to-EBITDA: 2.03 (27% above median its 10-year median of 1.60)
GF Value™: €1.01 vs. price of €0.17 (83.7% below fair value)
Industry Position: 23.8% above the Drug Manufacturers median (#522 of 681)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
59GF Score
Get the complete analysis for FRA:VV5
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
